published on 01/05/2023 at 11:18 from SARTORIUS STED BIO (EPA:DIM)

Half-year liquidity contract statement for Sartorius Stedim Biotech

Sartorius Stedim Biotech SA
Half-year liquidity contract statement for Sartorius Stedim Biotech

05-Jan-2023 / 11:18 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Aubagne, January 1, 2023

Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2022:

11,901 shares
€ 6,837,423.41
Number of executions on buy side on semester: 4,259
Number of executions on sell side on semester: 4,361
Traded volume on buy side on semester: 166,507 shares for € 56,282,984.47
Traded volume on sell side on semester: 174,847 shares for € 59,810,740.92

As a reminder, the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:

20,241 shares
€ 3,286,293.04
Number of executions on buy side on semester: 4,639
Number of executions on sell side on semester: 4,205
Traded volume on buy side on semester: 186,508 shares for € 64,215,074.25
Traded volume on sell side on semester: 169,628 shares for € 57,532,559.42

The following resources appeared on the liquidity account when the activity started:

0 shares
€ 10,000,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.

Contact

Petra Müller

Head of Investor Relations

+49 (0)551.308.6035

Petra.mueller2@sartorius.com

Sartorius Stedim Biotech S.A.

Z.I. Les Paluds

Avenue de Jouques, CS 91051

13781 Aubagne Cedex, France

Phone: +33.(0)4.42.84.56.00

Fax: +33.(0)4.42.84.56.19

www.sartorius.com

	Buy side			Sell side
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
TOTAL	4,259	166,507	56,282,984.47	4,361	174,847	59,810,740.92
01/07/2022	28	711	210,185.82	26	1,500	448,695.00
04/07/2022	7	305	93,946.10	33	1,200	370,344.00
05/07/2022	6	363	115,513.86	42	2,000	640,140.00
06/07/2022	34	1,400	445,396.00	15	500	161,800.00
07/07/2022	35	1,600	524,704.00	38	1,600	529,648.00
08/07/2022	33	1,200	392,316.00	35	1,600	528,624.00
11/07/2022	13	600	201,300.00	18	1,200	404,316.00
12/07/2022	29	1,300	437,294.00	26	1,200	406,680.00
13/07/2022	39	1,500	502,605.00	19	1,000	337,700.00
14/07/2022	37	1,700	568,497.00	25	1,339	450,386.04
15/07/2022	12	700	232,603.00	33	1,300	435,994.00
18/07/2022	38	1,300	431,665.00	12	200	68,800.00
19/07/2022	25	900	290,646.00	33	1,400	460,614.00
20/07/2022	-	-	-	24	900	304,209.00
21/07/2022	14	405	135,670.95	90	2,900	1,026,600.00
22/07/2022	-	-	-	13	800	304,072.00
25/07/2022	53	1,756	640,975.12	2	100	37,100.00
26/07/2022	18	1,000	363,000.00	22	1,100	400,697.00
27/07/2022	10	500	181,900.00	37	1,500	551,220.00
28/07/2022	20	1,016	372,526.56	51	2,400	897,792.00
29/07/2022	-	-	-	32	1,400	537,698.00
01/08/2022	12	601	233,188.00	28	1,200	469,596.00
02/08/2022	37

See all SARTORIUS STED BIO news